D-Index & Metrics Best Publications
Medicine
Italy
2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 112 Citations 49,307 1,182 World Ranking 2955 National Ranking 66

Research.com Recognitions

Awards & Achievements

2023 - Research.com Medicine in Italy Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Cancer

Silvio Danese focuses on Internal medicine, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease and Immunology. His Internal medicine research incorporates elements of Gastroenterology, Placebo and Surgery. His work on Randomized controlled trial and Clinical endpoint is typically connected to Maintenance therapy as part of general Surgery study, connecting several disciplines of science.

His work carried out in the field of Ulcerative colitis brings together such families of science as Young adult, Colitis and Intensive care medicine. His biological study spans a wide range of topics, including Tumor necrosis factor alpha and Cancer research. His Crohn's disease study combines topics from a wide range of disciplines, such as Prospective cohort study, Clinical trial, Radiology and Cohort study.

His most cited work include:

  • Vedolizumab as induction and maintenance therapy for ulcerative colitis. (1388 citations)
  • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management (1239 citations)
  • Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. (861 citations)

What are the main themes of his work throughout his whole career to date?

Silvio Danese mainly investigates Internal medicine, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease and Gastroenterology. His study in the field of Vedolizumab, Infliximab, Adalimumab and Adverse effect also crosses realms of In patient. His Ulcerative colitis research is multidisciplinary, incorporating elements of Placebo, Tofacitinib, Colitis and Ustekinumab.

The study incorporates disciplines such as Immunology and Intensive care medicine in addition to Inflammatory bowel disease. His Crohn's disease study incorporates themes from Magnetic resonance imaging, Clinical trial, Surgery and Cohort study. His Gastroenterology study frequently draws connections between adjacent fields such as Colonoscopy.

He most often published in these fields:

  • Internal medicine (48.32%)
  • Ulcerative colitis (37.11%)
  • Inflammatory bowel disease (35.87%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (48.32%)
  • Ulcerative colitis (37.11%)
  • Inflammatory bowel disease (35.87%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Ulcerative colitis, Inflammatory bowel disease, Gastroenterology and Crohn's disease. His Vedolizumab, Ustekinumab, Adverse effect and Adalimumab study in the realm of Internal medicine interacts with subjects such as In patient. Silvio Danese interconnects Tofacitinib, Colitis, Bioinformatics and Surrogate endpoint in the investigation of issues within Ulcerative colitis.

The various areas that Silvio Danese examines in his Inflammatory bowel disease study include Inflammation and Intensive care medicine. His work deals with themes such as Biopsy, Endoscopy and Ultrasound, which intersect with Gastroenterology. His studies deal with areas such as Dermatology and Colonoscopy as well as Crohn's disease.

Between 2019 and 2021, his most popular works were:

  • Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. (142 citations)
  • Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. (94 citations)
  • Management of IBD during the COVID-19 outbreak: resetting clinical priorities. (64 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

His main research concerns Inflammatory bowel disease, Internal medicine, Ulcerative colitis, Crohn's disease and Gastroenterology. His Inflammatory bowel disease study results in a more complete grasp of Disease. The Cohort, Ustekinumab, Prospective cohort study and Clinical trial research Silvio Danese does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as Maintenance therapy, therefore creating a link between diverse domains of science.

The concepts of his Ulcerative colitis study are interwoven with issues in Colitis, Adverse effect, Ultrasound, Magnetic resonance imaging and Diarrhea. Many of his research projects under Crohn's disease are closely connected to Patient-reported outcome with Patient-reported outcome, tying the diverse disciplines of science together. His Gastroenterology research is multidisciplinary, relying on both Biomarker, Biopsy, Balance and Magnetic resonance enterography.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer.
The New England Journal of Medicine (2013)

2142 Citations

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

A. Dignass;G. Van Assche;J.O. Lindsay;M. Lémann.
Journal of Crohns & Colitis (2010)

1672 Citations

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)

1442 Citations

Epithelial NEMO links innate immunity to chronic intestinal inflammation

Arianna Nenci;Christoph Becker;Andy Wullaert;Ralph Gareus.
Nature (2007)

1124 Citations

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn;Chinyu Su;Bruce E. Sands;Geert R. D’Haens.
The New England Journal of Medicine (2017)

1080 Citations

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Remo Panaccione;Subrata Ghosh;Stephen Middleton;Juan R. Márquez.
Gastroenterology (2014)

839 Citations

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

Julián Panés;Damián García-Olmo;Gert Van Assche;Jean Frederic Colombel.
The Lancet (2016)

759 Citations

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Jean Frédéric Colombel;Bruce E. Sands;Paul Rutgeerts;William Sandborn.
Gut (2017)

673 Citations

Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

J. Panes;Y. Bouhnik;W. Reinisch;J. Stoker.
Journal of Crohn's and Colitis (2013)

645 Citations

Tolerogenic dendritic cells: cytokine modulation comes of age

Sergio Rutella;Silvio Danese;Giuseppe Leone.
Blood (2006)

636 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Silvio Danese

Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet

University of Lorraine

Publications: 242

William J. Sandborn

William J. Sandborn

University of California, San Diego

Publications: 232

Jean-Frederic Colombel

Jean-Frederic Colombel

Icahn School of Medicine at Mount Sinai

Publications: 194

Brian G. Feagan

Brian G. Feagan

University of Western Ontario

Publications: 177

Severine Vermeire

Severine Vermeire

KU Leuven

Publications: 173

Markus F. Neurath

Markus F. Neurath

University of Erlangen-Nuremberg

Publications: 138

Gerhard Rogler

Gerhard Rogler

University of Zurich

Publications: 121

Peter L. Lakatos

Peter L. Lakatos

McGill University

Publications: 114

Javier P. Gisbert

Javier P. Gisbert

Autonomous University of Madrid

Publications: 114

Geert R. D'Haens

Geert R. D'Haens

University of Amsterdam

Publications: 102

Remo Panaccione

Remo Panaccione

University of Calgary

Publications: 96

David T. Rubin

David T. Rubin

University of Chicago

Publications: 93

Walter Reinisch

Walter Reinisch

Medical University of Vienna

Publications: 89

Alberto Mantovani

Alberto Mantovani

Humanitas University

Publications: 87

Subrata Ghosh

Subrata Ghosh

University College Cork

Publications: 84

Julián Panés

Julián Panés

University of Barcelona

Publications: 84

Trending Scientists

Sergei Vassilvitskii

Sergei Vassilvitskii

Google (United States)

Kook-Heui Lee

Kook-Heui Lee

Samsung (South Korea)

Adelia J. A. Aquino

Adelia J. A. Aquino

Texas Tech University

Kwanghee Lee

Kwanghee Lee

Gwangju Institute of Science and Technology

Joel H. Rothman

Joel H. Rothman

University of California, Santa Barbara

Piran C. L. White

Piran C. L. White

University of York

William Chia

William Chia

National University of Singapore

Christian Herrmann

Christian Herrmann

Ruhr University Bochum

Chung-Jung Tsai

Chung-Jung Tsai

Leidos (United States)

Nicholas Eyles

Nicholas Eyles

University of Toronto

Douglas A. Burns

Douglas A. Burns

United States Geological Survey

Gilles Billen

Gilles Billen

Université Libre de Bruxelles

Gordon T. Taylor

Gordon T. Taylor

Stony Brook University

Liesbet Goubert

Liesbet Goubert

Ghent University

Allison B. Sekuler

Allison B. Sekuler

McMaster University

Sergio Fabbrini

Sergio Fabbrini

Guido Carli Free International University for Social Studies

Something went wrong. Please try again later.